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Edited by Lukas HuberAbstract The diﬀerentiation of skeletal muscle has been
associated with altered phosphorylation status of individual
proteins. However, a global analysis of protein phosphorylation
during myogenesis has yet to be undertaken. Here, we report the
identiﬁcation of over 130 putative phosphoproteins from murine
C2C12 muscle cells. Cell extracts were fractionated on phos-
phoprotein enrichment columns and the resulting proteins were
detected by two-dimensional gel electrophoresis and silver stain,
and identiﬁed by liquid chromatography coupled to electrospray
tandem mass spectrometry. The early diﬀerentiation of C2C12
myoblasts was found to be accompanied by changes in the
phosphorylation or expression of numerous proteins including
cytoskeletal, heat shock and signaling proteins, the pp32 family
of nuclear phosphoproteins, several disease-associated gene
products and other characterized and uncharacterized proteins.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Skeletal myogenesis has served as a useful model for the
study of cellular diﬀerentiation. Myogenic precursor cells un-
dergo a distinctive diﬀerentiation program characterized by
exit from the cell cycle and cell–cell fusion to form multinu-
cleate myotubes. This process has been extensively studied at
the transcriptional level [1–3]. Transcriptional control of
muscle speciﬁcation and development is exerted by the myo-
genic regulatory factors (MRFs) MyoD, Myf5, Myogenin and
MRF4 [4], and by myocyte enhancer factor-2 (MEF-2) [5].
Expression of MyoD or Myf5 promotes assumption of myo-
blast characteristics, whereas diﬀerentiation of myoblasts to
myotubes is linked to the expression of myogenin and MRF4
[4].
In addition to the transcriptional paradigm, several lines
of evidence indicate that kinase-dependent signaling events
also regulate myogenesis. For example, the serine/threonine
kinase p38a/SAPK2 is activated upon induction of
diﬀerentiation and p38a inhibitors block skeletal muscle* Corresponding author. Fax: +1-613-737-8023.
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doi:10.1016/j.febslet.2004.08.019diﬀerentiation [6–9]. p38c/SAPK3 (ERK6) expression is
associated with and appears to promote muscle diﬀerentia-
tion [10,11]. Akt activity has been implicated in myogene-
sis [12,13]. Inhibition of the protein tyrosine kinase Src
blocks myotube formation, suggesting that tyrosine phos-
phorylation is required for complete muscle diﬀerentiation
[14].
An obvious question arising from these observations is the
identity of proteins that are phosphorylated during skeletal
myogenesis. MEF2A and MEF2C can be phosphorylated by
p38 and this potentiates their pro-myogenic activity [15,16].
Recently, SAPK2/p38 was shown to phosphorylate MRF4
[17]. Although MEF2 and MRFs are essential for myogenesis,
they are unlikely to be the only targets of phosphorylation.
However, no large-scale analysis of protein phosphorylation in
skeletal myogenesis has been conducted as yet.
In the present study, we utilized both phosphoprotein
binding columns and anti-phosphotyrosine immunoprecipita-
tion to prepare phosphoprotein-enriched samples for proteo-
mic analysis by comparative two-dimensional gel
electrophoresis (2DGE) and LC-MS/MS. These methods re-
vealed a large set of known and putative phosphoproteins that
are expressed during myoblast growth and early myogenesis.
Together, these results indicate that the diﬀerentiation process
in the skeletal muscle lineage may be regulated by an extensive
alteration of the endogenous phosphoproteome.2. Materials and methods
2.1. Cells and antibodies
C2C12 cells were obtained from ATCC and maintained as previ-
ously described [18]. Diﬀerentiation was induced by replacing growth
medium (DMEM, 10% FBS) with diﬀerentiation medium (DMEM,
2% horse serum). Anti-phosphotyrosine antibody PY100 was pur-
chased from Cell Signalling Technology (Beverly, MA).2.2. Phosphoprotein enrichment
To obtain cell lysates enriched for phosphoproteins, Phosphoprotein
Puriﬁcation Kit 37101 was purchased from Qiagen (Mississauga, Ont.)
and used in accordance with the manufacturer’s instructions. Brieﬂy,
cells were washed, lysed using the supplied lysis buﬀer, and centrifuged
to remove insoluble material. Protein lysate was loaded onto the
supplied phosphoprotein binding columns, washed, and eluted. The
eluate containing putative phosphoproteins was concentrated and de-
salted using the supplied ultraﬁltration columns (10 kDa cut-oﬀ).ation of European Biochemical Societies.
Fig. 1. Phosphoprotein content varies between growing and diﬀeren-
tiating myoblasts. Protein was extracted from C2C12 cells after 0 or 24
h culture in diﬀerentiation medium and loaded onto phosphoprotein
enrichment columns as described in Section 2. Column eluate was
concentrated using 10 kDa cut-oﬀ ultraﬁltration columns and sub-
jected to 2DGE on a pH 3–10 isoelectric focusing gradient and an
8–16% polyacrylamide gel gradient. Proteins were visualized by silver
stain.
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Cells were washed twice with PBS and lysed by the addition of 1%
TX-100 lysis buﬀer (1% Triton X-100, 50 mM HEPES, 150 mM NaCl,
10% glycerol, 1 mM EGTA, 1.5 mMMgCl2, 20 mM NaF, and 10 mM
sodium pyrophosphate, PMSF, aprotinin, pepstatin, leupeptin, and
sodium vanadate). Cells were incubated in lysis buﬀer for 20 min on
ice, then scraped and collected into 1.5 ml tubes. Samples were further
incubated for 10 min at 4 C, then centrifuged for 5–10 min at
20 000· g. 20 ll of agarose-bound PY100 mAb was added to 0.8 mg of
postnuclear protein lysate and incubated at 4 C overnight. Pellets
were washed three times in 1% TX-100 lysis buﬀer and resuspended in
Laemmli reducing sample buﬀer.
2.4. Electrophoresis
For 2DGE, samples were diluted in IEF buﬀer (7 M urea, 2 M
thiourea, 4% CHAPS, and 1% DTT) and absorbed into 17 cm
ReadyStripTM IPG strips (Bio-Rad) following the manufacturer’s di-
rections. Isoelectric focusing was performed on a Protean IEF Cell
(Bio-Rad) with the following program: 200 V for 1 h, 500 V for 1 h,
5000 V ramp for 5 h, and 5000 V for 80 000 VH. For separation by
molecular weight, 10% SDS–PAGE gels or 8–16% gradient precast gels
(Bio-Rad) were used in a Protean II electrophoresis cell (Bio-Rad).
2.5. Silver stain
Silver stain was performed as previously described [19].
2.6. In-gel digest
Selected protein spots were excised manually and in-gel digested with
trypsin using the Investigator Progest automated digestor (Genomic
Solutions, Ann Arbor, MI). Brieﬂy, the automated digestion procedure
was as follows. The gel pieces were destained with 1:1 solution of 30
mM potassium ferricyanide and 100 mM sodium thiosulfate [20],
washed 3 times with water and shrunk with acetonitrile. The gel pieces
were reswollen with 20 lL of 50 mM NH4HCO3 containing 20 ng/lL
of sequencing grade trypsin (Promega, Madison WI). Peptides were
ﬁrst extracted with 5% acetic acid (50 lL) and then with 5% acetic acid
in 50% methanol (50 lL). The extracts were pooled and evaporated to
dryness. The samples were stored at )20 C prior to analysis.
2.7. NanoLC-MS/MS analysis of in-gel digests
Samples were redissolved with 0.2% formic acid in 5% acetonitrile
(10 lL) and analyzed by nanoLC-MS/MS using a CapLC liquid
chromatograph (Waters) coupled with a Q-TOF Ultima hybrid
quadrupole time-of-ﬂight mass spectrometer (Waters). The samples
were ﬁrst injected onto a 0.3 5 mm C18 micro pre-column cartridge
(Dionex/LC Packings) to remove salts and other soluble contaminants.
The trap was then brought on-line with a 75 mm 150 mm C18 Nano-
Series column (Dionex/LC-Packings) and the peptides were separated
by gradient elution (5–55% acetonitrile, 0.2% formic acid in 45 min).
The mass spectrometer was set to operate in survey mode and MS/MS
spectra were automatically acquired on doubly, triply, and quadruply
charged ions.
The MS/MS fragment ion spectra were searched against the NCBI
nr protein sequence database using the MASCOT database search
engine (Matrix Science, London, UK). The lists of identiﬁed proteins
were then critically evaluated by hand.3. Results
3.1. Identiﬁcation of proteins after phosphoprotein enrichment
Protein lysates were prepared from C2C12 cultures after 0 or
24 h in diﬀerentiation-inducing medium and phosphoprotein
enrichment was performed as described. Proteins were sepa-
rated by 2DGE and visualized by silver stain (Fig. 1). Spots
were excised from replicate gels and peptides were extracted by
in-gel digestion for analysis by HPLC-ESI-MS/MS. 272 silver
stained gel spots were cut and 591 identiﬁcations representing
190 diﬀerent proteins were made (many proteins were identi-
ﬁed multiple times as they were present in more than one gel
and/or in more than one spot per gel). 132 proteins that gave
both quality MS/MS spectra and consistent silver-stain ex-pression patterns are listed in Tables 1–4. Of these proteins, 73
have been described in the literature as phosphoproteins, 31
are uncharacterized or poorly characterized at the protein le-
vel, two are thought to be non-phosphorylated, and for 26 no
information on phosphorylation status was found.
Each protein was characterized as to whether its apparent
abundance increased, decreased or remained unchanged be-
tween growth and diﬀerentiation conditions (Tables 1–3).
Since silver staining is known to be non-linear, only the
strongest changes were considered signiﬁcant; 68/82 (83%) of
the proteins listed in Tables 2 and 3 were detected exclusively
under growth or diﬀerentiation conditions, respectively. As
expected, many phosphoproteins did not signiﬁcantly change
in abundance between 0 and 24 h of myogenesis (Table 1). A
large number of proteins that were detected in proliferating
cells displayed a loss in phosphorylation or expression at 24 h
of diﬀerentiation (Table 2). Some such as nucleophosmin [21]
and small glutamine-rich tetratricopeptide repeat containing
protein [22] are known to be involved in cell cycle progression.
Lamin C phosphorylation has been associated with mitosis
[23]. BIN1 was detected in proliferating but not in diﬀerenti-
ating myoblasts and is known to be a phosphoprotein associ-
ated with myogenesis [24].
3.2. Detection of a pSer site in PEA-15
Automated LC-MS/MS can identify large numbers of pro-
teins with a high degree of conﬁdence, but speciﬁc sites of
phosphorylation are rarely detected since phosphopeptides do
Table 1
Proteins identiﬁed in both undiﬀerentiated and diﬀerentiating C2C12
Heat shock and chaperone
Calreticulin
Heat shock protein 1b
Stress-induced phosphoprotein 1
Tumor rejection antigen gp96
Proteasome
Proteasome subunit, a type 2
Proteasome subunit, a type 4
Proteasome subunit, a type 5
Proteasome subunit, a type 6
Proteasome subunit, b type 3
Structural and mechanical
Myosin light chain alkali
Myosin regulatory light chain-like
Similar to tropomyosin 4
Tropomyosin a
Tropomyosin b
Tropomyosin b2
Tropomyosin 5
Tubulin, a2
Translation
Eukaryotic translation elongation factor 1 b2
Eukaryotic translation initiation factor 2, subunit 2
Ribosomal protein, large, P1
Ribosomal protein, large, P2
Other functions
Acidic leucine-rich nuclear phosphoprotein 32 family, member A
Barrier to autointegration factor 1
Cathepsin D
Hepatoma-derived growth factor
Nascent polypeptide-associated complex a
p32-RACK (complement component 1 q subcomponent binding
protein)
ras-GTPase-activating protein SH3-domain binding protein
Tumor protein, translationally-controlled 1
Valosin containing protein
Unnamed gene products
Unnamed protein similar to septin 6
Table 2
Proteins exclusively or preferentially detected in undiﬀerentiated
C2C12
Cytoskeleton/regulatory
Caldesmon
Collapsin response mediator protein 2
Myosin regulatory light chain polypeptide 9
Nuclear distribution gene E homolog 1
Cytoskeleton/structural
Tubulin, a6
Putative b-actin
Actin-like
c-Actin
Drebrin A
Villin 2
Heat shock and chaperone
DNA K-type molecular chaperone grp78
DNA K-type molecular chaperone hsc70
Metabolic
Pyruvate dehydrogenase, b polypeptide
Similar to a enolase
Nuclear and chromatin
Dosage compensation-related protein DPY30
Heterogeneous nuclear ribonucleoprotein U
Lamin C
Nucleophosmin 1
RAN binding protein 1
Similar to small nuclear ribonucleoprotein F
Proteasome
Proteasome subunit, b type 6
Proteasome subunit, b type 7
Proteasome subunit, a type 3
Translation
Eukaryotic translation elongation factor 2
Eukaryotic translation initiation factor 3 subunit 4
Eukaryotic translation initiation factor 3 subunit 5
Eukaryotic translation initiation factor 4e
Signaling and other functions
Calcium-regulated heat stable protein 24 kD
COP9 signalosome subunit 4
Craniofacial development protein 1
High mobility group protein 1
Phosphoprotein enriched in astrocytes 15
Proliferation-associated 2G4
SH3 domain protein 3
SH3 domain protein 9 (BIN1)
Small glutamine-rich tetratricopeptide repeat containing protein
Transcription elongation factor B (SIII) polypeptide 2
Ubiquitin conjugating enzyme 3b
Vacuolar protein sorting 4b
Unnamed gene products
RIKEN 2410002K23 (similar to HSP75)
RIKEN 2610024N24 (similar to RANBP3b)
RIKEN G430041M01 (similar to transformer-2 a)
Unnamed protein similar to tumor protein D52
Unnamed protein similar to eTIF-3 subunit 1
Unnamed protein similar to gp96
Unnamed protein similar to tumor protein D52-like 2
Unnamed protein similar to CG7519-PA
Unnamed protein similar to caldesmon
Unnamed protein 5031425D22Rik
Unnamed protein similar to putative transcription intermediary factor
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phosphate moiety. However, site-speciﬁc phosphorylation of
one protein was readily detected. Phosphoprotein enriched in
astrocytes 15 (PEA-15) is a DED-domain protein with known
phosphorylation sites at Ser104 and Ser116 [25]. Although no
peptides covering Ser104 were seen, two out of three mass
spectra covering the Ser116 region indicate the presence of
phosphoserine at the 116 site (Fig. 2). Ser116 is a CaMKII
substrate and is required for the anti-apoptotic activity of
PEA-15 [25].
3.3. Proteins exhibiting altered gel mobility
Proteins whose electrophoretic mobility changed between
growing and diﬀerentiating cells (Fig. 3 and Table 4) were
identiﬁed by matching silver stain patterns to protein identi-
ties. Such observations directly demonstrate a physical alter-
ation to the protein such as post-translational modiﬁcation or
protein cleavage. The Niemann–Pick type C2 protein was
observed to exhibit two forms of diﬀerent isoelectric point (pI)
in undiﬀerentiated myoblasts but three pI forms during dif-
ferentiation. Lamin A was seen to have three pI forms, one of
which was only detected in undiﬀerentiated cells. Three mo-
bility forms of SET were detected in undiﬀerentiated C2C12
and in one experiment a unique mobility form of SET was seenin diﬀerentiating cells. Two SET-interacting proteins were also
detected: acidic leucine-rich nuclear phosphoprotein 32 family
member A (Table 1) and prothymosin-a (detected sporadically
under each condition, not shown in tables).
Table 3
Proteins preferentially or exclusively detected in diﬀerentiating C2C12
Cytoskeleton/regulatory
Cortactin
Cytoskeleton/structural
a-Actin
Tubulin a
Tubulin b2
Tubulin a3
Tubulin b
Heat shock and chaperone
a-B crystallin
HSP 27
Metabolic
Triosephosphate isomerase
Translation
Eukaryotic translation initiation factor 3 subunit 3
Similar to eukaryotic translation initiation factor 3 subunit 1
Signaling and other functions
14-3-3b
14-3-3e
Autophagy Apg3p/Aut1p-like
Cathepsin Z
Divalent cation tolerant protein CUTA
Epithelial protein lost in neoplasm
Heterogeneous nuclear ribonucleoprotein C
Methyl-CpG binding domain protein 3
Prosaposin
Protein kinase C and casein kinase substrate in neurons 2
SAPK3/ERK6/p38c
Similar to Sid3177p
Similar to TATA box binding protein associated factor
Sorting nexin 9
Telomerase binding protein p23
U2af1 protein
unc-33-like phosphoprotein (CRMP-4)
Unnamed gene products
RIKEN 2610019P18 (similar to trinucleotide repeat containing 5)
RIKEN 2310039E09 (similar to polymerase I and transcript release
factor)
RIKEN 2310047C17 (similar to periaxin)
Unnamed protein similar to RAN-BP3A
Table 4
Proteins exhibiting changes in electrophoretic mobility during early
myogenesis
Cytoskeleton/regulatory
Moesin
Stathmin
Cytoskeleton/structural
Tubulin b5
Vimentin
Heat shock and chaperone
Heat shock protein 1a
Nuclear
Acidic nuclear phosphoprotein 32 family member B
Acidic nuclear phosphoprotein 32 family member E
Chromobox homolog 1
Lamin A
Nucleolin
Transcription factor BTF3
Signaling and other functions
14-3-3f
Niemann–Pick type C2
PDGF-associated protein
Protein disulﬁde isomerase precursor
SET
Suppression of tumorigenicity 13
Unnamed gene products
RIKEN 2610029G23
Unnamed protein product similar to eTIF2 subunit 1a
Fig. 2. NanoLC-MS/MS analysis of a tryptic phosphopeptide from PEA-15.
most informative fragment ions are indicated in the MS/MS spectrum. The s
has been transformed into a pyroglutamic acid.
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heterodimer of NACa (Table 1) and the basic transcription
factor 3, splice isoform b (BTF3b) (Table 4) [26]. Although a
splice isoform of NACa termed skNAC is thought to be a
muscle-speciﬁc transcription factor [27], the NACa peptides
detected here were from the C-terminal region common to
both isoforms and the 2DGE spot position was closer to that
expected for the ubiquitous isoform. BTF3b appeared as a
single spot in growing cells, but as a pair of spots with diﬀerent
pI in diﬀerentiating cells.Product ion spectrum of the doubly protonated ion at m/z 568.2. The
equence of the peptide is shown in the inset. The N-terminal glutamine
Fig. 4. Phosphotyrosine proﬁling during C2C12 myoblast diﬀerentia-
tion. C2C12 cells were cultured in diﬀerentiation medium for 0, 24, 48
or 72 h. Tyrosine phosphorylated proteins were immunoprecipitated at
the indicated time points from C2C12 protein lysates. Proteins were
separated by SDS–PAGE on an 8% gel and silver stained. Bands of
interest were identiﬁed by LC-MS/MS.
Fig. 3. Close-up view of two-dimensional gels shows proteins exhib-
iting altered isoelectric points and/or gel mobility between 0 and 24 h
of myoblast diﬀerentiation. Silver-stained protein spots were identiﬁed
by LC-MS/MS. (A) Calcium-regulated heat-stable protein; (B) tran-
scription factor BTF3; (C) Coﬁlin; (D) Stathmin 1; (E) SH3 domain
protein 3; (F) Niemann–Pick C2; and (G) a-B-crystallin. Altered mo-
bility is evident relative to spots (A) and (C) which are invariant.
142 L.G. Puente et al. / FEBS Letters 574 (2004) 138–1443.4. Anti-phosphotyrosine immunoprecipitation
In addition to the phospho-column puriﬁcation approach,
we also investigated the utility of phospho-antibody immu-
noprecipitations (IPs) as a strategy for the isolation/enrich-
ment of phosphoproteins. C2C12 cells were grown, then
switched to diﬀerentiation-inducing medium and cultured for
varying amounts of time. Tyrosine-phosphorylated proteins
were immunoprecipitated, separated by one-dimensional
SDS–PAGE, and detected by silver stain (Fig. 4). Bands
exhibiting strong changes in intensity were excised, digested
and identiﬁed by nanoLC-ESI-MS/MS. The eﬀectiveness of
this method was reduced due to a background signal of
abundant proteins. However, several non-background pro-
teins were observed. Tyrosine phosphorylation of cortactin
was detected at 24 h of diﬀerentiation. Phosphorylated cort-
actin was also detected by aﬃnity column enrichment (Table
3) and by PY20 anti-phosphotyrosine IP (not shown). Several
components of the Arp2/3 complex were detected. Both Arp3
and subunit 2 (p34-Arc) appeared at 24 h of diﬀerentiation.
Arp2 was detected at all time points but only weakly at time
0. The actin-binding phosphoprotein drebrin was detected in
the aﬃnity column-based screen solely in undiﬀerentiated
cells (Table 2) but was also detected during diﬀerentiation in
the PY100 IP (Fig. 2). Interestingly, drebrin appears at a
slightly higher MW in the phosphotyrosine IP at time 0
(Fig. 4), suggesting that a multiply phosphorylated form of
drebrin may be present during growth that becomes less
phosphorylated upon diﬀerentiation.4. Discussion
4.1. Phosphoprotein enrichment
All large-scale analyses of phosphoprotein regulation rely
on selective enrichment of phosphoproteins and recently,
several strategies to accomplish this have been presented.
Immunoprecipitation is eﬀective for enrichment of tyrosine-
phosphorylated proteins. Covalent modiﬁcation of phos-
phorylated serine and threonine residues by b-elimination/
Michael addition may be used to add biotin for aﬃnity
capture or to create novel proteolysis sites for later detection
[28–30]. Immobilized metal aﬃnity chromatography (IMAC)
can be employed to retain negatively charged peptides aftermasking non-phosphate negatively charged residues by
methylation [31]. The aﬃnity columns used in the present
study oﬀer the advantage of not requiring covalent modiﬁ-
cation of the sample; this reduces sample processing time,
circumvents issues of insuﬃcient blocking or excessive la-
beling, and avoids creating covalent adducts that can inter-
fere with the interpretation of mass spectra. Similar
advantages were noted by Metodiev et al. [32] when pre-
paring samples for MALDI analysis. The detection of a
protein following any enrichment process is not on its own
suﬃcient evidence to prove the presence of a phosphorylated
residue. In some cases, phosphorylation sites are immedi-
ately evident (Fig. 2) but in most cases further steps such as
phosphopeptide enrichment are required. In this respect, the
IMAC strategy has been successfully applied to the large-
scale phosphorylation-site-speciﬁc analysis of phospho-pep-
tides [31], which was not examined here. Clearly, the use of
multiple phosphoprotein enrichment techniques in series may
be advantageous [33].
Comparative analysis of two-dimensional gels is a common
technique for comparing protein expression between two bio-
logical conditions. In the present study, silver staining was
suﬃcient to identify a large number of changes in protein
abundance and/or gel mobility after phosphoprotein enrich-
ment. In future studies, diﬀerence gel electrophoresis (DIGE)
could be used to identify additional smaller alterations in
protein abundance [34].
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myogenesis
A large number of proteins whose post-translational modi-
ﬁcation and/or expression changed during the ﬁrst 24 h of
myogenesis were identiﬁed. Several patterns were observed
that may have biological implications.
Cytoskeleton. Myogenesis is characterized by a substantial
change in cell morphology. The present data indicate that the
known cytoskeleton-regulating factors, moesin, drebrin, cal-
desmon, DRP-2, nuclear distribution gene E homolog 1, Arp2/
3, and cortactin, are expressed in diﬀerentiating muscle and
suggest that these proteins participate in myogenesis in a
phosphorylation-regulated manner. Tyrosine phosphorylation
of cortactin (Fig. 4 and Table 3) is thought to be mediated by
Src [35], suggesting that Src may be active during myogenesis.
This ﬁnding supports recent evidence that pTyr signaling plays
a role in myogenesis [14].
Genetic diseases. Two proteins linked to human genetic
disease, Niemann–Pick type C2 (NPC2) and lamin A, were
observed to be expressed in myoblasts and to exhibit altered
electrophoretic mobility during myogenesis (Table 4). Muta-
tions in the cholesterol-binding glycoprotein NPC2 cause a
fatal syndrome whose symptoms can include sudden loss of
muscle tone. Mutations in Lamin A have been associated with
a number of muscular dystrophy syndromes [36].
SET complex and chromatin remodeling. The SET complex is
a recently described protein complex that appears to inﬂuence
transcription, nucleosome assembly, DNA replication, and
apoptosis [37,38]. Three proteins detected in the present study,
SET, LANP (Anp32a) and prothymosin-a, are members of
this complex. Therefore, the SET complex may regulate my-
ogenesis through one or more of its activities. SET and LANP
are also found in the INHAT (inhibitor of acetyltransferases)
complex [39,40]. Interestingly, it is well established that the
histone deacetylases HDAC4 and HDAC5 repress skeletal
myogenesis and that diﬀerentiation requires loss of this re-
pressive activity [41–43]. Thus, it is very plausible that INHAT
activity might also regulate myogenesis. Methyl-CpG binding
domain protein 3 (MBD3), (Table 3) has also been implicated
in transcriptional repression and chromosomal remodeling [44]
and may be regulated by phosphorylation [45].
Regulators of apoptosis. PEA-15 [25], a-B-crystallin [46–48],
and prosaposin [49,50] are thought to be anti-apoptotic.
Crystallin has previously been associated with myogenesis
[46–48]. Interestingly, ectopic expression of PEA-15 inhibits
serum-withdrawal induced apoptosis [51] and C2C12 myo-
blasts respond to serum-withdrawal by entering diﬀerentia-
tion. Previous work done in our group [18] revealed that
transient caspase activation is in fact required for muscle
diﬀerentiation. Therefore, the anti-apoptotic proteins ob-
served in the present study may modulate the eﬀects of
transient caspase activity.
Similarity to neuronal diﬀerentiation. Stathmin-like 2,Anp32e,
Anp32a (LANP), CRMP-2, CRMP-4, and nuclear distribution
geneEhomolog 1havepreviously been associatedwithneuronal
development. Here, we ﬁnd that these proteins are also ex-
pressed in muscle and exhibit altered phosphorylation and/or
expression duringmyogenesis. Therefore,muscle and nervemay
share some common mechanisms for diﬀerentiation. Future
studies of additional tissue types will further distinguish devel-
opmental proteins that are lineage speciﬁc from those that are
common to all cells or to speciﬁc subsets of cells.4.3. Conclusion
The phosphoprotein aﬃnity column enrichment strategy
described herein coupled to 2DGE-HPLC-ESI-MS/MS was
eﬀective in revealing a large number of proteins that exhibit
altered post-translational modiﬁcation and expression during
myogenesis. These results oﬀer multiple implications for the
biology of myogenesis and present several avenues for future
investigations.
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